Preclinical experience with two selective progesterone receptor modulators on breast and endometrium

Steroids

Volumn 65, Issue 10-11, 2000, Pages 733-740

  Kloosterboer, Helenius J ^a   Deckers, Godefrides H ^a   Schoonen, Willem G E J ^a   Hanssen, Robert G J M ^a   Rose, Ursula M ^a   Verbost, Pieter M ^a   Hsiu, Jeng G ^b   Williams, Robert F ^b   Hodgen, Gary D ^b  

^a NV ORGANON   (Netherlands)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Antiprogestin; Breast; DMBA; Endometrium; Fertility; Monkeys; Progesterone receptor modulators; Rats; Tumo rs

Indexed keywords

11BETA [4 (DIMETHYLAMINO)PHENYL] 4',5' DIHYDRO 6BETA METHYLSPIRO[ESTRA 4,9 DIENE 17BETA,2'(3'H) FURAN] 3 ONE; ANTIGESTAGEN; ANTINEOPLASTIC AGENT; DESOGESTREL; DIMETHYLBENZ[A]ANTHRACENE; ESTRADIOL; GLUCOCORTICOID RECEPTOR; MIFEPRISTONE; ORG 33628; PROGESTERONE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MODULATOR; RU 45781; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; BIRTH CONTROL; BREAST CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENDOMETRIUM; FEMALE; LUTEAL PHASE; MENSTRUATION; MONKEY; NONHUMAN; OVARY FOLLICLE DEVELOPMENT; OVULATION INDUCTION; RAT; RECEPTOR AFFINITY;

ANIMALS; BREAST NEOPLASMS; CELL DIVISION; CELL SIZE; CONTRACEPTIVE AGENTS, FEMALE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENDOMETRIUM; ESTRENES; FEMALE; FURANS; HORMONE ANTAGONISTS; HUMANS; MACACA FASCICULARIS; MENSTRUATION; MENSTRUATION-INDUCING AGENTS; NEOPLASMS, EXPERIMENTAL; RATS; RECEPTORS, PROGESTERONE; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

ANIMALIA; MACACA FASCICULARIS;

EID: 0033645769     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(00)00189-6     Document Type: Conference Paper

References (30)

1. Antiprogestins: Their mechanism of action and the consequences for compound selection by in vitro and in vivo studies
2. Synthesis of antiprogestational steroids
3. Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors
4. Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether
5. Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore
6. Endocrine defects in mice carrying a null mutation for the progesterone receptor gene
7. Absence of gonadotropin surges and gonadotropin-releasing hormone self-priming in ovariectomized (OVX), estrogen (E2)-treated, progesterone receptor knockout (PRKO) mice
8. Mammary gland development is mediated by both stromal and epithelial progesterone receptors
9. Pharmacological properties of a new selective antiprogestagen: Org 33628
10. Pharmacology of two new very selective antiprogestagens: Org 31710 and Org 31806
11. 50 values of several synthetic (anti)-progestagens in vitro in CHO and MCF-7 cells and in vivo in rabbits and rats
12. Noncompetitive antiestrogenic effect of RU 486 in blocking the estrogen-stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrate monkeys
13. Induction of menstruation by an antiprogesterone (RU 486) in monkeys
14. Antiovulatory actions of RU 486: The pituitary is not the primary site of action in vivo
15. Atomic structure of progesterone complexed with its receptor
16. Screening of antiprogestagens by receptor studies and bioassays
17. The biological activity of 7α-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone
18. Characterization of ligand binding, DNA binding and phosphorylation of progesterone receptor by two novel progesterone receptor antagonist ligands
19. Novel antiprogestins Org 31806 and 31710: Interaction with mammalian progesterone receptor and DNA binding of antisteroid receptor complexes
20. The molecular biology of RU 486. Is there a role for antiprogestins in the treatment of breast cancer?
21. Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21
22. Treatment of breast cancer with different antiprogestins: Preclinical and clinical studies
23. Mechanism of action and clinical effects of antiprogestins on the non-pregnant uterus
24. Development and characterization of an in vitro ovulation model using mouse ovarian follicles
25. Reproductive phenotypes of the progesterone receptor null mutant mouse
26. A chronic, low-dose regimen of the antiprogestin ZK 137 316 prevents pregnancy in rhesus monkeys
27. Effects of antiprogestagens during the peri-ovulation period in female rats
28. Time-dependent ovulation inhibition after single dose administration of antiprogestagens in rats
29. Pharmacokinetics of mifepristone after low oral doses
30. Safety, tolerability, and pharmacokinetics of a novel, selective antiprogestagen (Org 31710) in healthy male volunteers